• Zenas BioPharma filed a prospectus supplement November 6, 2026, for up to $200 million in at-the-market common stock sales.
• Sales will run through Jefferies under the existing sales agreement dated October 8, 2025.
• The previous $200 million offering was terminated, with approximately $153.2 million sold and approximately $46.8 million unsold.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-123885), on November 06, 2026, and is solely responsible for the information contained therein.